Concentration-dependent synergy and antagonism within a triple antifungal drug combination against Aspergillus species: Analysis by a new response surface model

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 6, 2007, Pages 2053-2064

  Meletiadis, Joseph ^a   Stergiopoulou, Theodouli ^a   O'Shaughnessy, Elizabeth M ^a   Peter, Joanne ^a   Walsh, Thomas J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CASPOFUNGIN; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS TERREUS; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SENSITIVITY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SPECTROPHOTOMETRY;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; ASPERGILLUS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ANTAGONISM; DRUG INTERACTIONS; DRUG SYNERGISM; HUMANS; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; PEPTIDES, CYCLIC; PYRIMIDINES; TRIAZOLES;

EID: 34250166147     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00873-06     Document Type: Article

References (42)

1. Antachopoulos, C., J. Meletiadis, T. Sein, E. Roilides, and T. J. Walsh. 2007. Concentration-dependent effects of caspofungin on the metabolic activity of Aspergillus species. Antimicrob Agents Chemother. 51:881-887.
2. Arikan, S., M. Lozano-Chiu, V. Paetznick, and J. H. Rex. 2002. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob. Agents Chemother. 46:245-247.
3. Bekersky, I., R. M. Fielding, D. E. Dressler, J. W. Lee, D. N. Buell, and T. J. Walsh. 2002. Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans. Antimicrob Agents Chemother. 46:828-833.
4. Chandrasekar, P. H., J. L. Cutright, and E. K. Manavathu. 2004. Efficacy of voriconazole plus amphotericin B or micafungin in a guinea-pig model of invasive pulmonary aspergillosis. Clin. Microbiol. Infect. 10:925-928.
5. Clemons, K. V., M. Espiritu, R. Parmar, and D. A. Stevens. 2005. Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis. Antimicrob. Agents Chemother. 49:4867-4875.
6. Cuenca-Estrella, M., A. Gomez-Lopez, G. Garcia-Effron, L. Alcazar-Fuoli, E. Mellado, M. J. Buitrago, and J. L. Rodriguez-Tudela. 2005. Combined activity in vitro of caspofungin, amphotericin B, and azole agents against itraconazole-resistant clinical isolates of Aspergillus fumigatus. Antimicrob. Agents Chemother. 49:1232-1235.
7. Dannaoui, E., O. Lortholary, and F. Dromer. 2004. In vitro evaluation of double and triple combinations of antifungal drugs against Aspergillus fumigatus and Aspergillus terreus. Antimicrob. Agents Chemother. 48:970-978.
8. Forestier, E., V. Remy, O. Lesens, M. Martinot, Y. Hansman, B. Eisenmann, and D. Christmann. 2005. A case of Aspergillus mediastinitis after heart transplantation successfully treated with liposomal amphotericin B, caspofungin and voriconazole. Eur. J. Clin. Microbiol. Infect. Dis. 24:347-349.
9. Greco, W. R., G. Bravo, and J. C. Parsons. 1995. The search for synergy: a critical review from a response surface perspective. Pharmacol. Rev. 47:331-385.
10. Groll, A. H., and T. J. Walsh. 2002. Antifungal chemotherapy: advances and perspectives. Swiss Med. Wkly. 132:303-311.
11. Hajdu, R., R. Thompson, J. G. Sundelof, B. A. Pelak, F. A. Bouffard, J. F. Dropinski, and H. Kropp. 1997. Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872). Antimicrob. Agents Chemother. 41:2339-2344.
12. Herbrecht, R., S. Natarajan-Ame, Y. Nivoix, and V. Letscher-Bru. 2003. The lipid formulations of amphotericin B. Expert Opin. Pharmacother. 4:1277-1287.
13. Johnson, M. D., C. MacDougall, L. Ostrosky-Zeichner, J. R. Perfect, and J. H. Rex. 2004. Combination antifungal therapy. Antimicrob. Agents Chemother. 48:693-715.
14. Kirkpatrick, W. R., S. Perea, B. J. Coco, and T. F. Patterson. 2002. Efficacy of caspofungin alone and in combination with voriconazole in a guinea pig model of invasive aspergillosis. Antimicrob. Agents Chemother. 46:2564-2568.
15. Leveque, D., Y. Nivoix, F. Jehl, and R. Herbrecht. 2006. Clinical pharmacokinetics of voriconazole. Int. J. Antimicrob. Agents 27:274-284.
16. MacCallum, D. M., J. A. Whyte, and F. C. Odds. 2005. Efficacy of caspofungin and voriconazole combinations in experimental aspergillosis. Antimicrob. Agents Chemother. 49:3697-3701.
17. Manavathu, E. K., G. J. Alangaden, and P. H. Chandrasekar. 2003. Differential activity of triazoles in two-drug combinations with the echinocandin caspofungin against Aspergillus fumigatus. J. Antimicrob. Chemother. 51:1423-1425.
18. Markovich, S., A. Yekutiel, I. Shalit, Y. Shadkchan, and N. Osherov. 2004. Genomic approach to identification of mutations affecting caspofungin susceptibility in Saccharomyces cerevisiae. Antimicrob. Agents Chemother. 48:3871-3876.
19. Marr, K. A., M. Boeckh, R. A. Carter, H. W. Kim, and L. Corey. 2004. Combination antifungal therapy for invasive aspergillosis. Clin. Infect. Dis. 39:797-802.
20. Marr, K. A., T. Patterson, and D. Denning. 2002. Aspergillosis. Pathogenesis, clinical manifestations, and therapy. Infect. Dis. Clin. N. Am. 16:875-894, vi.
21. Meadows, S. L., C. Gennings, W. H. Carter, Jr., and D. S. Bae. 2002. Experimental designs for mixtures of chemicals along fixed ratio rays. Environ. Health Perspect. 110(Suppl. 6):979-983.
22. Meletiadis, J., J. W. Mouton, J. F. Meis, B. A. Bouman, J. P. Donnelly, and P. E. Verweij. 2001. Colorimetric assay for antifungal susceptibility testing of Aspergillus species. J. Clin. Microbiol. 39:3402-3408.
23. Meletiadis, J., J. W. Mouton, J. F. Meis, and P. E. Verweij. 2003. In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates. Antimicrob. Agents Chemother. 47:106-117.
24. Meletiadis, J., J. W. Mouton, D. T. A. te Dorsthorst, and P. E. Verweij. 2005. Assessing combination of antifungal drugs against yeast and filamentous fungi: comparison of different drug interaction models. Med. Mycol. 34:133-152.
25. Meletiadis, J., V. Petraitis, R. Petraitiene, P. Lin, T. Stergiopoulou, A. M. Kelaher, T. Sein, R. L. Schaufele, J. Bacher, and T. J. Walsh. 2006. Triazole-polyene antagonism in experimental invasive pulmonary aspergillosis: in vitro and in vivo correlation. J. Infect. Dis. 194:1008-1018.
26. Meletiadis, J., D. T. A. te Dortshorst, and P. E. Verweij. 2006. The concentration-dependent nature of amphotericin B-itraconazole interaction in vitro against Aspergillus fumigatus: Isobolographic and response surface analysis of complex pharmacodynamic interactions. Int. J. Antimicrob. Agents. 28:439-449.
27. Minto, C., and J. Vuyk. 2003. Response surface modelling of drug interactions. Adv. Exp. Med. Biol. 523:35-43.
28. Motulsky, H., and A. Christopoulos. 2003. Fitting models to biological data using linear and nonlinear regression. A practical guide to curve fitting. GraphPad Software Inc., San Diego, CA.
29. NCCLS. 2002. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard. NCCLS document M38-A. National Committe for Clinical Laboratory Standards, Wayne, PA.
30. O'Shaughnessy, E. M., J. Meletiadis, T. Stergiopoulou, J. Peter, and T. J. Walsh. 2006. Antifungal interactions within the triple combination of amphotericin B, caspofungin and voriconazole against Aspergillus species. J. Antimicrob. Chemother. 58:1168-1176.
31. Patterson, T. F., W. R. Kirkpatrick, M. White, J. W. Hiemenz, J. R. Wingard, B. Dupont, M. G. Rinaldi, D. A. Stevens, J. R. Graybill, et al. 2000. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. Medicine (Baltimore) 79:250-260.
32. Perea, S., G. Gonzalez, A. W. Fothergill, W. R. Kirkpatrick, M. G. Rinaldi, and T. F. Patterson. 2002. In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp. Antimicrob. Agents Chemother. 46:3039-3041.
33. Petraitiene, R., V. Petraitis, A. H. Groll, T. Sein, R. L. Schaufele, A. Francesconi, J. Bacher, N. A. Avila, and T. J. Walsh. 2002. Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia. Antimicrob. Agents Chemother. 46:12-23.
34. Schaffner, A., and A. Bohler. 1993. Amphotericin B refractory aspergillosis after itraconazole: evidence for significant antagonism. Mycoses 36:421-424.
35. Scheven, M., and F. Schwegler. 1995. Antagonistic interactions between azoles and amphotericin B with yeasts depend on azole lipophilia for special test conditions in vitro. Antimicrob. Agents Chemother. 39:1779-1783.
36. Sims-McCallum, R. P. 2003. Triple antifungal therapy for the treatment of invasive aspergillosis in a neutropenic pediatric patient. Am. J. Health Syst. Pharm. 60:2352-2356.
37. Sionov, E., S. Mendlovic, and E. Segal. 2006. Efficacy of amphotericin B or amphotericin B-intralipid in combination with caspofungin against experimental aspergillosis. J. Infect. 53:131-139.
38. Sivak, O., K. Bartlett, V. Risovic, E. Choo, F. Marra, D. S. Batty, Jr., and K. M. Wasan. 2004. Assessing the antifungal activity and toxicity profile of amphotericin B lipid complex (ABLC; Abelcet) in combination with caspofungin in experimental systemic aspergillosis. J. Pharm. Sci. 93:1382-1389.
39. Steinbach, W. J., D. A. Stevens, and D. W. Denning. 2003. Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001. Clin. Infect. Dis. 37(Suppl. 3):S188-S224.
40. Tascini, C., E. Tagliaferri, R. Iapoce, A. Leonildi, and F. Menichetti. 2003. Caspofungin in combination with itraconazole and amphotericin B for the treatment of invasive aspergillosis in humans, with a method to test ex vivo synergism. Clin. Microbiol. Infect. 9:901-902.
41. White, D. B., H. K. Slocnm, Y. Brun, C. Wrzosek, and W. R. Greco. 2003. A new nonlinear mixture response surface paradigm for the study of synergism: a three drug example. Curr. Drag Metab. 4:399-409.
42. Wiederhold, N. P., D. P. Kontoyiannis, J. Chi, R. A. Prince, V. H. Tam, and R. E. Lewis. 2004. Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J. Infect. Dis. 190:1464-1471.